Targeting cancer-associated fibroblasts to enhance immunotherapy in head and neck cancers
Targeting cancer-associated fibroblasts to enhance immunotherapy in head and neck cancers
Despite significant advances in immunotherapy, response rates in head and neck squamous cell carcinoma (HNSCC) remain critically low, with only ~15% of patients benefiting from current treatments such as anti-PD-1 inhibitors. This limited efficacy is primarily attributed to the immunosuppressive tumour microenvironment, particularly the abundance of myofibroblastic cancer-associated fibroblasts (myCAFs), which hinder immune infiltration and protect tumour cells from immune-mediated destruction. Strategies to deplete or reprogram myCAFs could significantly improve immunotherapy responses; however, the lack of specific myCAF markers has posed a major challenge.
This study identified MAGED4B, a cancer/testis antigen, as a promising dual marker of tumour cells and myCAFs in HNSCC. Single-cell RNA sequencing revealed selective MAGED4B expression in myCAF and malignant populations, with minimal expression in other stromal or immune cells. Immunohistochemistry analysis of 53 HNSCC patient samples validated this finding, with MAGED4B expression detected in tumour cells (43/53) and myCAFs (25/53). These findings support MAGED4B as a novel target for therapeutic intervention in myCAF-rich HNSCC.
To explore its therapeutic potential, a murine oral cancer model was developed to mimic myCAF-rich tumours. A pDOM DNA fusion vaccine targeting MAGED4B elicited a robust CD8+ T cell response in vivo, as demonstrated by IFNγ ELISpot assays. In the absence of myCAFs, MAGED4B-targeted vaccination significantly reduced tumour growth (p=0.0414) and improved survival (p=0.0389), demonstrating the vaccine’s potential efficacy. However, the presence of myCAFs compromised vaccine efficacy, highlighting the immunosuppressive role of myCAFs within the tumour microenvironment.
To identify additional therapeutic targets for disrupting myCAF activity, a CRISPR/Cas9 screen was employed using TGF-β1-treated fibroblasts to identify regulators of the myCAF phenotype. Over 100 candidate genes were identified, including those implicated in the regulation of αSMA expression, with ongoing investigations prioritising the most promising hits for therapeutic targeting.
These findings suggest that MAGED4B-directed immunotherapy represents a dual-target strategy to overcome immunotherapy resistance by targeting both tumour cells and stromal barriers. HNSCC, characterised by extensive desmoplasia and frequent myCAF enrichment, poses a significant clinical challenge, particularly in patients resistant to conventional immunotherapy. The combination of MAGED4B-targeted vaccination with other immunotherapeutic approaches, such as immune checkpoint inhibitors, holds potential to enhance immune infiltration, disrupt stromal defences, and improve outcomes in therapy-resistant HNSCC.
University of Southampton
Buckingham, Josephine Frances
e0e5f0b1-ff44-48da-adb4-cadac56a6e06
2025
Buckingham, Josephine Frances
e0e5f0b1-ff44-48da-adb4-cadac56a6e06
Thomas, Gareth
2ff54aa9-a766-416b-91ee-cf1c5be74106
Savelyeva, Natalia
a1b6f225-e6f0-4862-8323-bd338e916ac8
Hanley, Chris
7e2d840d-e724-4389-a362-83741ccdf241
Buckingham, Josephine Frances
(2025)
Targeting cancer-associated fibroblasts to enhance immunotherapy in head and neck cancers.
University of Southampton, Doctoral Thesis, 269pp.
Record type:
Thesis
(Doctoral)
Abstract
Despite significant advances in immunotherapy, response rates in head and neck squamous cell carcinoma (HNSCC) remain critically low, with only ~15% of patients benefiting from current treatments such as anti-PD-1 inhibitors. This limited efficacy is primarily attributed to the immunosuppressive tumour microenvironment, particularly the abundance of myofibroblastic cancer-associated fibroblasts (myCAFs), which hinder immune infiltration and protect tumour cells from immune-mediated destruction. Strategies to deplete or reprogram myCAFs could significantly improve immunotherapy responses; however, the lack of specific myCAF markers has posed a major challenge.
This study identified MAGED4B, a cancer/testis antigen, as a promising dual marker of tumour cells and myCAFs in HNSCC. Single-cell RNA sequencing revealed selective MAGED4B expression in myCAF and malignant populations, with minimal expression in other stromal or immune cells. Immunohistochemistry analysis of 53 HNSCC patient samples validated this finding, with MAGED4B expression detected in tumour cells (43/53) and myCAFs (25/53). These findings support MAGED4B as a novel target for therapeutic intervention in myCAF-rich HNSCC.
To explore its therapeutic potential, a murine oral cancer model was developed to mimic myCAF-rich tumours. A pDOM DNA fusion vaccine targeting MAGED4B elicited a robust CD8+ T cell response in vivo, as demonstrated by IFNγ ELISpot assays. In the absence of myCAFs, MAGED4B-targeted vaccination significantly reduced tumour growth (p=0.0414) and improved survival (p=0.0389), demonstrating the vaccine’s potential efficacy. However, the presence of myCAFs compromised vaccine efficacy, highlighting the immunosuppressive role of myCAFs within the tumour microenvironment.
To identify additional therapeutic targets for disrupting myCAF activity, a CRISPR/Cas9 screen was employed using TGF-β1-treated fibroblasts to identify regulators of the myCAF phenotype. Over 100 candidate genes were identified, including those implicated in the regulation of αSMA expression, with ongoing investigations prioritising the most promising hits for therapeutic targeting.
These findings suggest that MAGED4B-directed immunotherapy represents a dual-target strategy to overcome immunotherapy resistance by targeting both tumour cells and stromal barriers. HNSCC, characterised by extensive desmoplasia and frequent myCAF enrichment, poses a significant clinical challenge, particularly in patients resistant to conventional immunotherapy. The combination of MAGED4B-targeted vaccination with other immunotherapeutic approaches, such as immune checkpoint inhibitors, holds potential to enhance immune infiltration, disrupt stromal defences, and improve outcomes in therapy-resistant HNSCC.
Text
Targeting Cancer-Associated Fibroblasts to Enhance Immunotherapy in Head and Neck Cancers - Josephine F Buckingham_Thesis_Upload
- Version of Record
Restricted to Repository staff only until 3 June 2028.
Text
Final-thesis-submission-Examination-Miss-Josephine-Buckingham
Restricted to Repository staff only
More information
Published date: 2025
Identifiers
Local EPrints ID: 502290
URI: http://eprints.soton.ac.uk/id/eprint/502290
PURE UUID: 7126eeee-4b50-4e2a-9a9f-449bbb683ba2
Catalogue record
Date deposited: 19 Jun 2025 17:13
Last modified: 17 Oct 2025 02:08
Export record
Contributors
Author:
Josephine Frances Buckingham
Thesis advisor:
Natalia Savelyeva
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics